Since the discovery of NF2’s involvement, many advances have been performed in the description of meningioma mutational landscape.1 The therapeutic management of refractory meningioma to iterative surgeries and radiotherapy sessions remains an unmet medical need in neurooncology. The gene discussed is NF2; the disease is meningioma.